RxDoctor Payments Data

Sidney Vinson, MD

Gastroenterology · Springdale, ARNPI 1215970561

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 44.1% of the total.

$5,383in general payments, 2019–2025

Across 308 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$398
  • Johnson & Johnson$382
  • Pfizer$290
  • Takeda Pharmaceuticals U.S.A., Inc.$281
  • Sanofi$193
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$5,19296%
  • Gifts$1914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,383 in reported general payments places this provider in the 60th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$219,430
Medicare patients
382
Services billed
9,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$306,479
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates201$12,651
Colestipol Hcl101$7,759
SutabSod Sulf/Pot Chloride/Mag Sulf47$7,405
Ursodiol40$6,918
Budesonide DrBudesonide34$4,660
Mesalamine ErMesalamine35$4,416
ClenpiqSod Picosulf/Mag Ox/Citric Ac25$4,336
Omeprazole304$2,312
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C16$2,245
Pantoprazole Sodium190$2,065
Misoprostol13$1,133
Azathioprine36$954
Famotidine62$829
Colesevelam Hcl15$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$382$306,47911 claims
Braintree Laboratories, Inc.Sutab$191$7,40547 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$398$2,24516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →